维奈克拉联合地西他滨与强化化疗在急性髓系白血病中的倾向性评分匹配分析
该研究比较了10天地西他滨联合维奈克拉(DEC10-VEN)与强化化疗(IC)在老年初诊急性髓系白血病(AML)患者中的疗效,采用治疗相关死亡率评分(TRMS)分层并进行倾向性评分匹配。结果显示DEC10-VEN组完全缓解率更高、复发率更低、30天死亡率更低且总生存期更长,在高危和低危TRM患者中均优于IC。
要点
- DEC10-VEN较IC显著提高CR/CRi(81% vs 52%)并降低复发率(34% vs 56%)。
- DEC10-VEN组30天死亡率仅1%,显著低于IC组的24%。
- DEC10-VEN组中位OS为12.4个月,IC组为4.5个月(HR=0.48)。
核心结论
- 在老年初诊AML患者中,DEC10-VEN较强化化疗获得更好的缓解率、更低的早期死亡率和更长的总生存期。
- 在高危和低危TRM患者中DEC10-VEN均显示优于IC的CR/CRi、30天死亡率和OS。
- 高危与低危TRM患者接受DEC10-VEN的结局相当。
研究设计与样本
- 回顾性比较研究,DEC10-VEN组n=85,IC对照组n=85,采用倾向性评分匹配。
- DEC10-VEN方案为每日维奈克拉联合地西他滨20 mg/m2×10天诱导,巩固期为地西他滨5天。
- IC组接受含阿糖胞苷≥1 g/m2/d的方案。
- 采用经验证的治疗相关死亡率评分(TRMS)将患者分为高危或低危TRM。
主要发现
- DEC10-VEN组CR/CRi为81%,IC组为52%(P < .001)。
- DEC10-VEN组复发率为34%,IC组为56%(P = .01)。
- DEC10-VEN组30天死亡率为1%,IC组为24%(P < .01)。
- DEC10-VEN组中位OS为12.4个月,IC组为4.5个月(HR=0.48,95%CI 0.29-0.79,P < .01)。
- DEC10-VEN组中位年龄72岁(范围63-89),28%患者为IC高危TRM。
关键数值与推荐
- CR/CRi:DEC10-VEN 81% vs IC 52%,P < .001。
- 复发率:DEC10-VEN 34% vs IC 56%,P = .01。
- 30天死亡率:DEC10-VEN 1% vs IC 24%,P < .01。
- OS:DEC10-VEN 12.4个月 vs IC 4.5个月,HR=0.48,95%CI 0.29-0.79,P < .01。
临床怎么用
- 对老年初诊AML患者,DEC10-VEN可作为优于强化化疗的诱导方案选择。
- 对IC高危TRM的老年患者,DEC10-VEN尤其可能带来生存获益。
- 治疗决策时可结合TRMS评估患者TRM风险以辅助选择方案。
局限性
- 为倾向性评分匹配的回顾性比较,非随机对照试验。
- 样本量有限(每组n=85),结论需前瞻性研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Hypomethylating agents (HMA) with venetoclax is a new standard for older/unfit patients with acute myeloid leukemia (AML). However, it is unknown how HMA with venetoclax compare to intensive chemotherapy (IC) in patients who are "fit" or "unfit" for IC. We compared outcomes of older patients with newly diagnosed AML receiving 10-day decitabine with venetoclax (DEC10-VEN) vs IC. DEC10-VEN consisted of daily venetoclax with decitabine 20 mg/m2 for 10 days for induction and decitabine for 5 days as consolidation. The IC cohort received regimens containing cytarabine ≥1 g/m2 /d. A validated treatment-related mortality score (TRMS) was used to classify patients at high-risk or low-risk for TRM with IC. Propensity scores were used to match patients to minimize bias. Median age of the DEC10-VEN cohort (n = 85) was 72 years (range 63-89) and 28% patients were at high-risk of TRM with IC. The comparator IC group (n = 85) matched closely in terms of baseline characteristics. DEC10-VEN was associated with significantly higher CR/CRi compared to IC (81% vs 52%, P < .001), and lower rate of relapse (34% vs 56%, P = .01), 30-day mortality (1% vs 24%, P < .01), and longer overall survival (OS; 12.4 vs 4.5 months, HR = 0.48, 95%CI 0.29-0.79, P < .01). In patients at both at high-risk and low-risk of TRM, DEC10-VEN showed significantly higher CR/CRi, lower 30-day mortality, and longer OS compared to IC. Patients at both high-risk and low-risk of TRM had comparable outcomes with DEC10-VEN. In conclusion, DEC10-VEN offers better outcomes compared to intensive chemotherapy in older patients with newly diagnosed AML, particularly in those at high-risk of TRM.
引用
- Maiti A, Qiao W, Sasaki K, et al. Venetoclax with decitabine vs intensive chemotherapy in acute myeloid leukemia: A propensity score matched analysis stratified by risk of treatment-related mortality. Am J Hematol. 2020. PMID: 33264443. doi:10.1002/ajh.26061
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。